| mRNA |
IOX2 |
GDSC1000 |
pan-cancer |
AAC |
0.13 |
0.0003 |
| mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0003 |
| mRNA |
MS-275 |
gCSI |
pan-cancer |
AAC |
0.18 |
0.0007 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.001 |
| mRNA |
YM201636 |
GDSC1000 |
pan-cancer |
AAC |
0.11 |
0.001 |
| mRNA |
dabrafenib |
GDSC1000 |
pan-cancer |
AAC |
0.1 |
0.002 |
| mRNA |
PLX4720 |
GDSC1000 |
pan-cancer |
AAC |
0.1 |
0.002 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.003 |
| mRNA |
Cytarabine |
GDSC1000 |
pan-cancer |
AAC |
0.11 |
0.004 |
| mRNA |
BAY 61-3606 |
GDSC1000 |
pan-cancer |
AAC |
0.11 |
0.004 |